Kiniksa Pharmaceuticals Ltd (KNSA) Stock AnalysisKNSAKiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kiniksa Pharmaceuticals Ltd (KNSA) is a good buy right now due to its current price of $78.59, which is below the average analyst price target of $90. Additionally, the company's gross margin has improved to 90.32% in Q2 2026, and it reported a significant year-over-year revenue growth of 55% to $243.6 million. The main risk is its high forward P/E ratio of 59.52, indicating that the stock may be overvalued if growth slows.

4 analysts cover KNSA: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 53.50.